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Background: Many growth factors, such as bone morphogenetic protein (BMP)-2, have been shown to interact
with polymers of sulfated disacharrides known as heparan sulfate (HS) glycosaminoglycans (GAGs), which are found
on matrix and cell-surface proteoglycans throughout the body. HS GAGs, and some more highly sulfated forms of
chondroitin sulfate (CS), regulate cell function by serving as co-factors, or co-receptors, in GF interactions with their
receptors, and HS or CS GAGs have been shown to be necessary for inducing signaling and GF activity, even in the
osteogenic lineage. Unlike recombinant proteins, however, HS and CS GAGs are quite heterogenous due, in large
part, to post-translational addition, then removal, of sulfate groups to various positions along the GAG polymer.
We have, therefore, investigated whether it would be feasible to deliver a DNA pro-drug to generate a soluble
HS/CS proteoglycan in situ that would augment the activity of growth-factors, including BMP-2, in vivo.
Results: Utilizing a purified recombinant human perlecan domain 1 (rhPln.D1) expressed from HEK 293 cells with
HS and CS GAGs, tight binding and dose-enhancement of rhBMP-2 activity was demonstrated in vitro. In vitro,
the expressed rhPln.D1 was characterized by modification with sulfated HS and CS GAGs. Dose-enhancement of
rhBMP-2 by a pln.D1 expression plasmid delivered together as a lyophilized single-phase on a particulate tricalcium
phosphate scaffold for 6 or more weeks generated up to 9 fold more bone volume de novo on the maxillary
ridge in a rat model than in control sites without the pln.D1 plasmid. Using a significantly lower BMP-2 dose,
this combination provided more than 5 times as much maxillary ridge augmentation and greater density than
rhBMP-2 delivered on a collagen sponge (InFuse™).
Conclusions: A recombinant HS/CS PG interacted strongly and functionally with BMP-2 in binding and cell-based
assays, and, in vivo, the pln.247 expression plasmid significantly improved the dose-effectiveness of BMP-2
osteogenic activity for in vivo de novo bone generation when delivered together on a scaffold as a single-phase.
The use of HS/CS PGs may be useful to augment GF therapeutics, and a plasmid-based approach has been
shown here to be highly effective.
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Commercial augmentation of synthetic bone graft sub-
stitutes began with approval of rhBMP-7 delivered in a
putty of bovine type 1 collagen and carboxymethyl cellu-
lose (OP-1™) under a Humanitarian Device Exemption
by the FDA. This product was followed by the addition* Correspondence: decarlo@agentabiotechnologies.com
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reproduction in any medium, provided the orof recombinant human bone-morphogenetic protein-2
(rBMP-2) to reconstituted bovine collagen in the prod-
uct InFuse™ in 2002 for spine procedures. Finally, in
2005, platelet-derived growth factor (PDGF)-1 delivered
with a tricalcium phosphate crystal was approved for peri-
odontal regenerative procedures (Gem 21S™). InFuse™ was
subsequently approved for long-bone and oral surgical
procedures in 2004 and 2007, respectively.
Of the 3 drug-eluting bone graft products that have
been FDA approved, efficacy of each has been in ques-
tion either prior to approval (OP-1™ and Gem 21S™) orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
DeCarlo et al. BMC Biotechnology 2012, 12:60 Page 2 of 16
http://www.biomedcentral.com/1472-6750/12/60post-approval (InFuse™). Further, InFuse™, which was
designed to deliver high doses of BMP-2, has been
reported to have serious life-threatening side effects, and
is exceptionally expensive to use. Despite these risks
and limited predictability, the market for InFuse™ is
approaching $1 billion, demonstrating the demand from
clinicians in orthopedics and oral surgery for a new and
suitable synthetic bone graft substitute.
Many growth factors, such as BMP-2, have been
shown to interact with long chains of sulfated disachar-
rides known as heparan sulfate (HS) glycosaminoglycans
(GAGs), which are found on matrix and cell-surface pro-
teoglycans throughout the body [1-5]. HS GAGs regulate
cell function by serving as a co-factor, or co-receptor in
GF interactions with their receptors, and HS GAGs are
necessary to induce physiological signaling and growth
factor activity [1-7]. Much evidence has accumulated to
show that GF signaling is in fact controlled by HS, even
in the osteogenic lineage [8-11] or in chondrogenic dif-
ferentiation [12,13]. The interaction of BMPs with their
threonine-serine kinase BMP receptors is also thought
to be mediated by HS [13-16]. Also, HS is thought
to prevent diffusion of growth factors, such as the
BMPs, away from the regions where they are likely
to be required [17], and the concept of HSPG as a bio-
active vehicle for GF delivery has been substantiated
[12,13,18,19]. Highly sulfated forms of the proteoglycan
GAG chondroitin sulfate (CS) have also been implicated
in GF co-activation [20-23], though these interactions
are less well characterized.
Unlike recombinant proteins, HS and CS GAGs are
quite heterogenous due, in large part, to post-
translational addition, then removal, of sulfate groups to
various positions on the constituent monosaccharides,
orchestrated by a battery of enzymes in a tissue-, or cell-
specific manner [24]. Following addition of a linker
sequence at the canononical SGD sequence, variability
begins with initiation of a glycosaminoglycan polymer,
followed by chain elongation to varying lengths with
varying degrees of isomerization, deacetylation, and sul-
fation followed by desulfation throughout the chain [24].
We have, therefore, investigated whether it would be
feasible to deliver the DNA pro-drug to generate a sol-
uble PG in situ that would augment the activity of
growth-factors, including BMP-2, in vivo.
We report here on recombinant human perlecan do-
main 1 (rhPln.D1) binding and enhancing the activity
rhBMP-2 in vitro, and we report on the in vivo dose-
enhancement of rhBMP-2 by the pln.D1 expression plas-
mid delivered together as a lyophilized single-phase on
a particulate tricalcium phosphate scaffold to generate
de novo bone formation on the maxillary ridge in a
rat model.Methods
Synthesis and ELISA characterization of rhPln.D1
The recombinant proteoglycan rhPln.D1 was generated
from HEK 293 cells by an adenoviral expression system
originally designed to express the first 247 amino acids
of perlecan (initially named HSPG-2), and was charac-
terized as previously described displaying a CS:HS ratio
of approximately 2:1 [25]. Additional ELISA charac-
terization of the CS GAG chains was performed by the
following methods. The rabbit polyclonal antibody to
perlecan (CCN-1) was produced in house against puri-
fied human endothelial perlecan. The mouse monoclonal
antibody to perlecan domain I (clone A71) was pur-
chased from Thermo Scientific, Rockford, IL, USA.
Mouse monoclonal antibodies against heparan sulfate
(HS) (clone 10E4), heparinase (Hep) III generated HS
stubs (clone 3 G10), chondroitin sulfate (CS) types and
D (clone LY111) and CS type D (MO-225) were pur-
chased from Seikagaku Corp., Tokyo, Japan. The mono-
clonal antibody against CS types A and C (clone CS-56)
was purchased from Sigma-Aldrich, St. Louis, MO, USA.
Mouse monoclonal antibodies against heparin (clones
2Q546 and A7.10) were purchased from US Biological,
Marblehead, MA, USA and Merck Millipore Billerica,
MA, USA respectively. Mouse monoclonal antibodies
reactive to the linkage regions of chondroitin sulfate
stubs that remain after chondroitinase ABC digestion
(clones 1B5, 2B6 and 3B3) as well as CS antibody (clone
7D4) were gifts from Prof. Bruce Caterson, Cardiff
University, UK. Biotinylated anti-mouse or anti-rabbit
whole immunoglobulin (Ig) secondary antibodies and
streptavidin-horse radish peroxidase (SA-HRP) were pur-
chased from GE Healthcare, Little Chalfont Bucking-
hamshire, UK. Horseradish peroxidase (HRP) conjugated
goat anti-rabbit IgG antibodies were purchased from
Merck Millipore, Billerica, MA, USA. Endoglycosidase
enzymes, proteinase free chondroitinase ABC (C’ase
ABC) and heparinase III (Hep III) (EC 4.2.2.8), were pur-
chased from Seikagaku Corp., Tokyo, Japan. Samples
were digested with 50 mU/ml C’ase ABC in 0.1 M Tris
acetate, pH 8, at 37°C for 16 h to determine the presence
of CS. Samples were digested with 50 mU/ml Hep III in
10 mM Tris–HCl, pH 7.4, at 37°C for 16 h to determine
the presence of HS. Purified Pln 247 (10 μg/ml), with
and without endoglycosidase digestion, was coated onto
high-binding 96 well ELISA plates for 2 h at RT.
Wells were rinsed twice with Dulbecco’s phosphate
buffered saline (DPBS), pH 7.4, followed by blocking
with 0.1% (w/v) casein in DPBS for 1 h at RT. Wells
were rinsed with DPBS containing 1% (v/v) Tween 20
(PBST), followed by incubation with primary antibodies
diluted in 0.1% (w/v) casein in DPBS for 2 h at RT.
Wells were rinsed with PBST followed by incubation
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in 0.1% (w/v) casein in DPBS for 1 h at RT, rinsed with
PBST and then incubated with streptavidin-HRP (1:500)
for 30 min at RT. Binding of the antibodies to the
samples was detected using the colourimetric substrate,
2 mM 2,20-azino-di-3-ethylbenzthiazoline sulfonic acid
(ABTS) in 0.5 M sodium citrate pH 4.6, and absorbance
measured at 405 nm.
Ligand binding assays
Ligand binding assays were performed in polystyrene
microtiter wells as a modified enzyme linked immuno-
sorbent assay (ELISA) as previously described [25].
Either rhPln.247 or capture antibody CSI 001–71 (Anti-
body Shop) were coated overnight at 4°C onto the
surfaces in PBS/N3 at approximately 1–2 μg/ml. All
wells were then washed and blocked in PBS containing
0.1% Tween. Capture antibody was followed by
rhPln.247 (1 μg/ml, produced in our laboratory) in se-
quence, then rhBMP-2 (R&D Systems) or rhBMP-7
(R&D Systems) were serially diluted. Primary biotiny-
lated anti-BMP murine antibodies (US Biologicals) were
applied in PBS/Tween at a concentration of 0.5 μg/ml
overnight at 4°C. Alkaline phosphatase conjugated sec-
ondary antibody (Goat-α-mouse, Abcam) or streptavidin
(Abcam) was applied at a concentration of 1 μg/ml for
2 h then AP activity was monitored at 405 nm by
hydrolysis of the substrate 4-Nitrophenylphosphate
(Sigma) in 10 mM Tris, pH 9.5 with 5 mM MgCl2 (ELISA
Substrate buffer) using a Bio-Tek Instruments, Inc.
μQuant spectrophotometer (absorbance maximum of 3.0
ELISA units). Background BMP binding in the absence
of rhPln.247 was subtracted. Apparent dissociation con-
stants (Kd) were derived as previously described [26].
Osteoblast activation assays
Mineralization assays: MC3T3-E1 subclone 4 osteoblasts
(ATCC) were seeded to confluence, 2×104/well, in 2 cm2
tissue culture treated TPP dishes in Gibco Growth
Medium (Invitrogen custom product, MEM Alpha with-
out ascorbic acid). After 48 h, the medium was changed
to Mineralization medium (Growth Medium containing
50 μg/ml ascorbic acid, 3 mM NaHPO4) with 8 ng/ml
rhBMP-2 (R&D Systems). To three pairs of wells was
added rhPln.D1 (rhPln.198 produced in our laboratory)
to a final concentration of 1, 2, and 4 μg/ml. Cells were
cultured for an additional 6 days after which time the
cells were washed once in sterile water, fixed for 30 min-
utes in 10% neutral buffered formalin, washed twice
again with water, then stained for 2 minutes in 2% ali-
zarin red. Densitometry was performed after imaging
with a Kodak GelLogic 1500 and using Kodak MI soft-
ware for grid ROIs. Alkaline phosphatase (AP) activityassays: In a protocol similar to ligand binding assays
described above, microtiter wells were coated with a so-
lution of 140 nM rhPln.247 overnight, blocked, then a
dilution series of rhBMP-2 was captured overnight. In
parallel wells, an equivalent amount of BMP-2 (as vali-
dated by ELISA) was directly coated in the wells using an
identical dilution series. All wells were washed and
blocked again with PBS/Tween then washed with PBS
and seeded with pre-osteoblasts in alpha-MEM with 10%
serum, 2.5x104/well in 100 μl. After a 6 h seeding period,
media in all wells was replaced with Mineralization media
(after imaging to ensure even seeding). After 5 days incu-
bation, pre-osteoblast activation was determined by AP
activity released by pre-osteoblasts into the serum-free
medium. To measure relative AP activities, 20 μl condi-
tioned medium from each well was transferred to 80 μl of
ELISA Substrate buffer and color development allowed to
proceed for 24 h at 22°C. Kact for each condition was
determined from dilution series equilibrium point repre-
senting 50% maximum activity release.Bioactivated TCP particle preparation
To prepare bioactivated crystals for surgical implant-
ation in rats, a solution of rhBMP-2 (up to 50 ug per ml
of final TCP volume) with plasmid DNA lipoplexes (up
to 120 ug DNA per ml of final TCP volume plus lipid at
1:2 v:v DNA:lipid) was made and mixed with TCP parti-
cles (Impladent, Inc., 200–600 μm), usually 0.5 ml DNA
lipoplex solution for 1 ml of TCP. First, washed TCP
particles were loaded with rhBMP-2 and incubated for
20 min at 22°C. Second, the same TCP particles were
further bioactivated by adding either pln.247 plasmid
(pln.247 in pBI vector, Clontech) or an empty-vector
plasmid in a cationic lipoplex (prepared and incubated
for 20 min at 22°C (see DNA lipoplex preparation). The
TCP particles and solutions were well mixed and incu-
bated for 1 hr at 22°C. Greater than 90% of the biologics
within the loading solution were adsorbed to the TCP
particles when loading for in vivo application in this
manner. The bioactivated TCP particle mix was then
frozen at −80°C for 1 hr and lyophilized overnight at
−40°C with 100 x10-3 mBar pressure. The lyophilized
TCP particles carrying both rhBMP-2 and pln.D1 ex-
pression plasmid are designated throughout the article
as B-247. To measure biologic adsorption to the TCP,
then kinetic release of loaded biologics, excess bioactiva-
tion solution was removed from the TCP for biologic
concentration determination just prior to freeze-drying.
Adsorption and elution were densitometrically deter-
mined for BMP-2 by immunoblot analysis and for pln.
D1 plasmid from agarose gel analysis, where biologic
concentrations after TCP loading, then elution, were cal-
culated from standard curves.
Figure 1 A: Daily elution of BMP-2 per ml of TCP that had been
loaded then lyophilized with BMP-2 amounts ranging from
100 μg to 1 mg. B: Log-linear relationship between total pln.247
plasmid eluted after 3 days (y-axis) and pln.247 plasmid loaded
per ml of TCP (x-axis). C: Daily elution of pln.247 plasmid per ml of
TCP that had been loaded then lyophilized with approximately
205 μg pln.247 plasmid.
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Plasmid DNA was mixed with Lipofectamine 2000W
(Invitrogen) in a 1:2 v:v ratio in sufficient volume to mix
well with the TCP particles. The DNA and lipid suspen-
sion was incubated for 20 min at 22°C to allow for com-
plexing. Sucrose was added to the DNA lipoplex
solution to a final 2% w/v of the final crystal volume.
qPCR
qPCR reactions were performed with SYBR Green Mas-
ter (Sigma) mix using an initial denaturation of 95°C for
3 min then 50 cycles of 95°C for 30 sec and 63°C for
30 sec. The forward primer originated in the 50 untrans-
lated region (50-AAC tCC gCC CCA ttg ACg CA-30) and
the reverse primer originated within the transgene se-
quence (50-gCA tCt ggC tgg Cgg tCA Ct-30) of the
pln.247-mod expression plasmid (Figure 1). PCR cDNA
was generated from reverse transcription reactions using
random primers. Calculated thresholds (Ct) were deter-
mined automatically with the maximum curvature ap-
proach on a BioRad MyiQ™ qPCR machine.
Animal care and procedures
All animal studies were performed in compliance with
and under the oversight of the Institutional Animal Use
and Care Committee of the University of Alabama.
Retired breeder male Lewis rats (Charles River Labora-
tories), >250 g, were maintained in standard housing,
two per cage, with bedding changed 3x weekly. Food
and water were provided ad libitum and replaced as
needed. Rats for each procedure were chosen randomly,
and studies were performed in a double blind manner so
that the operator did not know which rat or location
was receiving experimental or control products. Rats
were anesthetized with isoflurane (4-5% induction, 2%
maintenance) for all procedures. Animals were moni-
tored daily for signs of distress and closely examined if
distress was apparent. Animals with infections or other
issues were excused from the study and euthanized prior
to harvesting the maxilla in accord with methods
approved by the AVMA Panel on Euthanasia and with
IACUC oversight.
Bone void surgical procedure
In anesthetized rats and in a sterile field, bilateral full-


































Figure 2 Ligand Binding Curves; A: rBMP-2 (solid line) and
rBMP-7 (dotted line) dilutions were bound in steady state to
immobilized rhPln.D1. Retained BMP was detected by anti-BMP
antibodies. Y-axis is Abs 405 nm; X-axis is rhBMP-2 and rhBMP-7
concentration in nM units. Equilibrium point (apparent Kd) is 0.4 nM
for binding of rBMP-2 in this example. B: Either rhPln.D1 (circle, solid
line) or a sample of HSPG (square, dashed line) were immobilized to
bound CS-0071 anti Pln.D1 antibody then bound in steady state to
dilutions of rBMP-2. Y-axis is Abs 405 nm; X-axis is rhPln.D1 and
HSPG concenration in nM units. In this example, apparent Kd for
BMP-2 binding with rhPln.D1 = 600 pM and for BMP-2 binding with
HSPG = 150 pM after subtracting background. Error bars represent
standard deviations of duplicates.
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diameter round bur rotating < 200 rpm with a saline drip
was used to create a void crater defect in the bone
approximately 2 mm wide and 1 mm deep. Surgical defects
were rinsed and wiped clean, then control or experimental
graft materials were placed and condensed to the level of
the natural bone. A 5 mm diameter GTR barrier mem-
brane was placed onto the bone covering the defect and
the flaps were closed and fixed with cyanoacrylate. The
treated animals were fed soft chow during the first week
post-surgery and healing permited for 2 or 3 weeks.
Maxillary ridge augmentation
In anesthetized rats, full-thickness tunnel flaps were
raised bilaterally on the edentulous maxillary ridges me-
sial to the first molar. Experimental and control bone
grafts were inserted under the flaps onto the bone sur-
face. Tunnel entrances through the gingiva were sealed
and healing permitted for various periods of time ran-
ging from 3 days to 12 weeks. The treated animals were
fed soft chow during the first week post-surgery.
CT analysis
Maxilla were harvested as whole units, and fixed in His-
tochoice (Amresco), for CT analysis. μCT isosurface
images were acquired using a 70 kVp-25ma-20 ms
protocol and reconstructed at 52 microns resolution
with a threshold of 600 voxel units under service con-
tract with Charles River Imaging. Three-dimensional (3-
D) isosurface rendered images were generated using an
isosurface threshold of 600 voxel. 3-D raw data were
imported into image processing software AmiraW for
segmentation and new bone was segmented manually.
Histological analysis
After harvesting and fixation, maxilla were prepared for
histological analysis by decalcification in 5% formic acid
and paraffin embedding. Embedded blocks were step
serially cut to produce 7 micron sections for staining
and analysis.
Results
BMP binding and activation by rhPln.D1 in vitro
We have previously shown that the soluble rhPln.D1
expressed from mammalian cells either by adenoviral in-
fection or by plasmid transfection binds to BMP-2 (ma-
ture form) and to the following growth factors; BMP-6,
BMP-14, FGF-2, VEGF 189, and PDGF-BB as described
[25]. The binding of rhBMP-2 to immobilized rhPln.D1
was tight (573 ± 51 pM apparent Kd), and was approxi-
mately 10 fold greater than binding to rhBMP-7
(Figure 2A). For comparison, binding of BMP-2 to a
commercial source of HSPG (150 nM) was approxi-
mately 4 fold more avid than binding to the rhPln.D1
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tween immobilized BMP-2 and soluble rhPln.D1,
demonstrated no measurable binding at all (data not
shown). As previously demonstrated for FGF-2, these
BMP-2 binding data and apparent Kd were similar for
two different rhPln.D1 recombinant proteoglycans
(rhPln.198 and rhPln.247 (see [25]) (not shown). Func-
tionally in cell culture, pre-osteoblasts were differen-
tiated to produce mineralized substrate by co-delivery of
rBMP-2 with the rhPln.D1 proteoglycan in vitro
(Figure 3A). Using alkaline phosphatase release as an al-
ternative assay for pre-osteoblast differentiation, thereFigure 3 A. Osteoblast Activation. A: Mineralization Assay. Left; pre-ost
8 ng/ml rhBMP-2 plus varying concentrations of the rhPln.D1. Dark stain re
staining. Right; Stained mineralization in the wells was quantified by densit
seen with low level BMP-2 alone. Star represents statistical difference betw
with either 0 or 1 μg/ml Pln.D1 (p = 0.02). Data represent replicates in thre
pre-osteoblasts was determined by AP activity released by pre-osteoblasts
BMP-2 dilutions immobilized either on plastic (BMP-2) or onto rhPln.D1-coa
confirmed by ELISA (not shown). Kact for each condition was determined fr
activity release (inset).was a 2.7 fold enhancement of the BMP-2 dose-effect-
iveness when rBMP-2 had been captured with immobi-
lized rhPln.D1 compared to the effect of BMP-2 only in
these assays, reported as Kact, (p = 0.03, 2-sided t-test)
(Figure 3B).
GAG characterization of rhPln.D1 CS and HS
Additional evidence of a recombinant perlecan core pro-
tein was provided by the polyclonal CCN-1 (Figure 4A).
The HS of the rhPln.D1 pool was reactive with antibody
clone 10E4 indicating the presence of N-sulfated glucosa-
mine residues, but was not reactive with mAb A7.10 oreoblasts were seeded evenly to confluence and treated for 6 days with
presents dose-dependent mineralization as a result of alizarin red
ometry. Data represent fold increase beyond the level of mineralization
een the mineralizing effects of both 2 and 4 μg/ml Pln.D1 conditions
e separate experiments. B. Alkaline Phosphatase Assay. Activation of
into serum-free medium after 5 days incubation. Conditions compared
ted wells (rhPln.D1/BMP-2). Equal levels of BMP-2 in wells was






























































































































































































A. Perlecan B.  Heparansulfate C. Chondroitin sulfate
Figure 4 ELISA characterisation of rPlnD1. A: Immunoreactivity of protein core using monoclonal anti-perlecan domain I (A71) and polyclonal
anti-perlecan antibody (CCN-1); B: HS GAG characterization using monoclonal antibodies against HS chains (10E4), HS/heparin (2Q546), heparin
(A7.10) and HS stub detection (light bars) after digestion with Hep III (3G10); C: CS GAG chain characterization using monoclonal antibodies
against CS tetrasaccharide type A-D (CS-56), CS hexasaccharide type C-C-A (LY111), CS hexasaccharide type C-A-D (MO-225), CS (7D4) and CS
stubs (1B5 (unsulfated), 2B6 (4S) and 3B3 (6S)) detected after no treatment (dark bars), or chondroitinase ABC digestion (light bars). Data corrected
for background absorbance and presented as mean ± standard deviation (n=3).
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heparin-like, regions of HS (Figure 4B). Digestion of HS
with Hep III exposed an HS stub epitope that was immu-
noreactive with mAb 3 G10 further confirming the HS
GAG character. The CS of the rhPln.D1 pool was reactive
with antibody clone CS-56, which reacts with CS types C,
D, and A (Figure 4C). However, the recombinant was not
reactive with antibody clone LY111 that recognizes a CS
type C and type A. Nor was the rhPln.D1 recognized by
mAb MO 225 suggesting lack of a reducing end CS-D
disaccharride. Upon CS GAG digestion with chondroiti-
nase ABC, there was weak immunoreactivity with mAb
3B3 (anti-GalNAc(6S) stub), and relatively less reactivity
with mAb 2B6 (anti-GalNAc(4S) stub) and no reactivity
with mAb 1B5 (anti-unsulfated stub).
Biologic retention and release of pln.D1 plasmid
and rBMP-2
Kinetic data demonstrated that the BMP-2 bound effi-
ciently to the TCP particles (at least 2.4 mg rhBMP-2
per ml of dry TCP bound in 2 hours at 4°C). The expres-
sion plasmid also adsorbed quickly, up to 240 μg/ml
TCP particles in 2 hours at 4°C. After lyophilization of
TCP particles that were adsorbed with rhBMP-2
amounts ranging from 100 μg up to 1 mg per ml of
TCP, the rhBMP-2 was slowly released into 37°C PBS
buffer (43 ± 2 μg/ml of TCP released in the first 3 days),
as detected by immunoblot analysis (Figure 1A). Thepln.D1 plasmid was also eluted slowly but, unlike with
BMP-2, was released in amounts directly proportional to
the amount of plasmid loaded (Figure 1B). Over the ini-
tial 3 days of elution of TCP augmented with 205 μg of
pln.247 plasmid, approximately 460 ng ± 30 ng plasmid
was released at 37°C (11.2%), mostly during the first
24 h (Figure 1C).
Substituting a GFP expression plasmid (EGFP-
pcDNA3.1+) for the pln.247 plasmid in vitro, the loaded
and lyophilized crystals, when placed with HEK cells in
culture wells, delivered biologically active plasmid to the
cells, evident by fluorescent protein expression as early
as 16 h incubation (not shown).
In vivo rhPln.D1 expression
PCR of biopsies taken up to 12 weeks after B-247 implan-
tation demonstrated the presence of retained plasmid
(data not shown). To specifically measure in vivo expres-
sion of perlecan RNA from the bioactivated TCP parti-
cles, a codon-modified pln.D1 expression plasmid was
used (pln.248-mod, Figure 5A and B) allowing discrimin-
ation of recombinant pln.D1 mRNA from native. TCP
particles loaded with 150 μg/ml of pln.248-mod expres-
sion plasmid and 75 μg/ml rhBMP-2 were implanted sub-
periosteally on the bone of the rat maxilla, and after three
days, the graft site was biopsied. Agarose gel analysis of
PCR using primers specific for the codon-modified













Figure 5 A: Plasmid map of the codon-modified perlecan D1 expression construct used for in vivo expression analysis. B: sequence of
the codon-modifed perlecan D1 transgene employed for in vivo expression analysis.
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strated a mean Ct of 21.4 ± 1.7 and a 64± 5 fold
increased level of codon-modified pln.D1 mRNA at the
experimental site relative to the contralateral control site
(p = 0.0005, one-side t-test of Ct, normalized by cyclophi-
lin cDNA (Ct) levels).
Bone void healing in the rat maxilla
A series of histomorphometric data were first obtained
by measuring osteoid generation in maxillary bone
wounds created with a 2 mm rotating bur. In these bone
void defects, TCP particles alone generated less than 5%
new osteoid after 3 weeks healing (Figure 6A, no plas-
mid, 0 μg/ml BMP-2). Addition of the pln.247 plasmid
(40 μg/ml) to the TCP (0, yes) generated similarly low
levels of osteoid fill, not significantly different than the
empty TCP particles. Combining low levels of rhBMP-2
with the TCP particles resulted in a mean defect fill of
40% while adding low levels of the pln.247 plasmid with
the rhBMP-2 resulted in almost twice as much osteoid
fill (70%) during three weeks of healing, suggesting that
pln.247 plasmid augmented BMP-2 osteogenic activity
in bone wound repair. The augmentation of rhBMP-2
activity in void repair was directly dependent on thedose of pln.247 plasmid co-presented with the rhBMP-2
(Figure 6B, p = 0.0017, one-way ANOVA). The commit-
ment to bone formation began in the first week and
osteoid was forming by day 14 (not shown).Maxillary Ridge Augmentation
Experimental and control bone grafts were inserted dir-
ectly on the crest of the maxillary ridge under full-
thickness flaps and healing was permitted for various
periods of time. Micro-CT analysis was performed on
extracted maxilla after 6–12 weeks healing (Figure 7A
and B). By micro-CT, analysis (voxel threshold >600),
the B-247 formula (169%± 33%) was 2.9 fold more ef-
fective in building new ridge height than the TCP/BMP-
2 only formula (58%± 2.7%; p = 0.0051) and 5.1 fold
more effective than InFuse™ (33%± 21%; p = 0.0019)
(Figure 7C). By micro-CT analysis after 6–12 weeks
healing, the volume of new bone generated by B-247
(9.0 ± 2.5 mm3) was 9.0 times greater than new bone
generated by the TCP particles with BMP-2 only
(1.0 ± 0.4 mm3; p = 0.02). The B-247 particles also gener-
ated 2.8 fold more new bone than the InFuse™
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Figure 6 Histomorphometric subject data of % osteoid fill after
3 weeks healing in a bone void model. A: wounds treated with
TCP particles loaded with (yes) or without (no) 40 μg/ml pln.247
plasmid in the presence (30-50 μg/ml) or absence (0) of rhBMP-2.
B: wounds treated with 30-50 μg/ml BMP-2 and varying doses of
pln.247 plasmid. Error bars represent standard deviations of 27 sites.
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http://www.biomedcentral.com/1472-6750/12/60The mean density of the new bone volume (including
marrow spaces) generated in 6–12 weeks by B-247 was
not significantly more dense than new bone generated
by the TCP/BMP-2 formula but was 4.3 fold more dense
than the new bone generated by InFuse™ (33 ± 20;
p = 0.008, one-way ANOVA) (not shown).
Histological analysis
By histological analysis, the TCP particles, not loaded
with any biologic, had no evidence of osteogenesis asso-
ciated with them in this model of de novo bone gener-
ation (Figure 8B). In contrast, the B-247 formula of
low-dose BMP-2 with pln.247 plasmid on TCP particles
was osteogenic by 3 weeks (Figure 9A, both right
and left) clearly developing a non-cartilagenous,intramembranous osteoid network that was integrated
into the crest of the maxilla (Figure 9B), was not
inflamed, and showed no osteoid of an ectopic nature.
By 6 weeks, the new bone generated by the B-247 par-
ticles (Figure 9C, right) had begun to mature showing
evidence of a central marrow space, while BMP-2-
loaded TCP (Figure 9C, left) was not osteogenic in this
model, even after 6 weeks incubation. Delivery of low-
dose BMP-2 plus the empty-vector plasmid on the TCP
particles as a control demonstrated moderate osteo-
genic activity at 6 weeks healing (Figure 9D, left),
slightly more than the BMP-2/TCP combination in this
animal (Figure 9D, right).
After 12 weeks, the B-247 particles were still asso-
ciated with the development of mature bone on top of
the existing maxillary ridge (Figure 10A and C, right),
and partially integrated with the new bone (Figure 10B).
Remnants of TCP particles remained embedded within
the new bone. Evidence of a developed foreign body
reaction was often seen in association with TCP/BMP-2
only condition (Figure 10A, 50 μg/ml BMP-2; Figure 10B,
100 μg/ml BMP-2).
BMP-2 delivered on a collagen sponge (InFuse™)
resulted in a loss of maxillary ridge height up to 3 weeks
incubation (not shown), but subsequent recovery gener-
ated moderate amounts of new bone by 6 weeks
(Figure 11A, right), and 12 weeks (Figure 11B, left). The
B-247 particles consistently generated more new bone
than did InFuse™ (Figure 11A), while InFuse™ was typic-
ally more effective by 6–12 weeks than BMP-2/TCP only
(Figure 11B).
In sites treated with BMP-2 doses with 50 μg/ml of
TCP volume (n = 25, Figure 12), the effect of the
pln.247 plasmid on BMP-2 osteogenic ridge height in-
crease measured histomorphometrically was statistically
and clinically greater than the BMP-2 only (2.9 fold
increase in ridge height, p < 0.0001) and the empty-
vector effect (2.2 fold increase in ridge height,
p < 0.0025) with no significant difference between treat-
ment with BMP-2 only or BMP-2 plus the empty-
vector plasmid (p = 0.46). InFuse™ treatment resulted
in a mean ridge height increase of 27%± 31, signifi-
cantly lower than the B-247 formulation (p < 0.0001,
data not shown).
The CBC and clinical chemistry safety data showed
values within normal limits for aging rats. The animals
showed no signs of toxicity or general morbidity.
Discussion
Recent work on HS demonstrated its inherent bent
shape and flexibility in solution emanating primarily
from the N-acetylated and less highly sulfated regions of
the GAG polymer [27]. While overall flexibility of the






















































































Figure 7 A and B: μCT isosurface images (left) and cross-sectional radiographs (right) acquired after 12 weeks of healing using a
70kVp-25ma-20ms protocol and reconstructed at 52 microns resolution with a threshold of 600 voxel units. Dotted lines outline
regions of new bone formation. A: Left ridge treatment - TCP loaded and lyophilized with 100 μg/ml of rhBMP-2. Right ridge treatment – B-247
treatment of TCP loaded and lyophilized with 100 μg/ml rhBMP-2 plus 100 μg/ml of pln.247 plasmid. B: Left ridge treatment – B-247 treatment of
TCP loaded and lyophilized with 50 μg/ml rhBMP-2 plus 100 μg/ml of pln.247 plasmid. Right ridge treatment – InFuse™. C: Percent increase in
maxillary ridge hight above normal (100%) after 6 to 12 weeks healing measured in μCT analysis for varying treatment conditions (n = 14). D:
Volume of new bone assessed by μCT analysis for three treatment conditions after 6 to 12 weeks healing measured in μCT analysis (n = 20).
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http://www.biomedcentral.com/1472-6750/12/60limited regionally. Analysis of the interactions of HS-like
polymers with growth factors has demonstrated an in-
timate interaction between the two, requiring multiple
contacts in sulfated regions [28-30]. Similar binding
complexity between HSPGs and BMP-2 is expected [16]and such could be implied from the high binding avidity
measured here.
Antibody characterization of the in vitro recombinant
with the anti-HS antibodies suggested this rhPln.D1 HS
is N-sulfated, within regions of N-acetylation [31,32],
Figure 8 Masson’s trichrome staining. A: Untreated maxillary
ridge, right and left. Bar = 0.5 mm. B: 3 weeks healing. TCP
particles only. Bar = 0.5 mm. No new osteoid evident. Pairs of
images are from same animal.
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http://www.biomedcentral.com/1472-6750/12/60but also that additional sulfation may be limited, as sug-
gested by the lack of interaction with the two heparin-
binding mAbs. Further, a proportion of the rhPln.D1
was shown to be expressed with CS, which was immu-
noreactive with mAb CS-56 [25], demonstrating the
presence of sulfated regions of either type C, D, or
A. While CS-56 prefers the octasaccharide sequence of
CS-type C-A-D-C or A-A-D-C, additional antibody
characterization of the rhPln.D1 GAGs demonstrated no
immunoreactivity with MO 225 which also prefers the
octasaccharide sequence of CS-type C-A-D-C but reacts
only weakly with the sequence A-A-D-C [33,34]. No
immunoreactivity by mAb LY111, which is an antibody
thought to prefer the CS-type C-C-A hexasaccharide with-
out the CS-D disaccharride [33], supports the presence of
the disulfated CS-D unit, possibly in the CS-A-A-D-C
octasaccharride configuration. Previous characterization
suggested a similarity in the rhPln.D1 generated in vitro
from HEK 293 cells and from primary endothelial cells
[25] but differences from this GAG characterization
expected with in vivo expression remains unclear.
While there is little evidence to support BMP-2
binding of CS, BMP-4 has been shown to interact
functionally with a highly sulfated CS [22] suggesting
that both the sulfated HS and CS of the rhPln.D1
core used here could be involved in functional BMP-2
interactions.
While the rhBMP-2 bound tightly to rhPln.D1 that
had been immobilized directly in solid phase ELISA, im-
mobilizing the BMP-2 directly to the polystyrene sub-
strate prevented the interaction with soluble rhPln.D1.
These data could be interpreted to support therequirement that multiple contacts exist between the
BMP-2 ligand and sulfated GAG chains that was dis-
cussed above. Direct immobilization of the growth factor
to a substrate in a ligand binding assay may limit the
freedom of the GAG chains to optimally bind the GF
ligand, likely through steric hindrance by the immo-
bilization surface.
Binding avidity between the rhPln.D1 and BMP-2 was
found to be significantly tighter than binding to BMP-7.
This was not expected because both BMP-2 and BMP-7
primary sequences each contain three conserved triplets
of basic amino acids in the N-terminal region near
the start of the conserved cysteine knot. The two N-
terminal triplets of BMP-7 are, however, more distant
from the knot than in BMP-2 and contain one less basic
amino acid substituted by Ser [16]. Further, newly
reported molecular docking analysis of heparin/HS with
BMP-2 demonstrates that non-conserved residues pro-
vide additional electropositive binding potential com-
pared to BMP-7 [35].
Calcium-based ceramic materials, such as hydroxyapa-
tite and tricalcium phosphate, are effective as osteocon-
ductive agents and work well alone as bone void fillers
but they are not osteoinductive (as demonstrated above).
Tricalcium phosphate has been shown to be a good
delivery vehicle for BMP-2, though, and the combination
is osteogenic [36-39]. While very high amounts of
rhBMP-2 could be adsorbed to the porous, unsintered
calcium phosphate apatite used in these experiments,
release of the BMP-2 appeared to be rate limiting. Incu-
bating lyophilized particles that had been loaded with
varying BMP-2 amounts ranging from 100 μg to 1 mg
per ml of TCP yielded similar quantities of BMP-2
released into solution over the first three days, unlike
the dose-dependent elution of the pln.247 plasmid that
was demonstrated. The fact that BMP-2 release was
most rapid during the second day of incubation and
decreased thereafter suggested that a TCP volume-
dependent pool of “early-release” rhBMP-2 had become
established during the loading and lyophilization
process. Similar loading and release characteristics were
obtained from a non-porous unsintered calcium phos-
phate apatite although released amounts were several
fold higher (data not shown), suggesting that the porous
TCP structure utilized in these experiments aided in re-
tention of BMP-2. These kinetics of early and controlled
BMP-2 release may have contributed to the efficacy and
safety of the technology.
To substantiate specific pro-drug activity of the
pln.247 plasmid, we have demonstrated the presence of
expression plasmid throughout a 12-week healing period
by PCR, and specific mRNA expression of the recombin-
ant core within the wound. However, we have not yet








Figure 9 Masson’s trichrome stain. A: 3 wk healing after both right and left sides received B-247 treatment of TCP loaded then lyophilized
with 50 μg/ml rhBMP-2 plus 100 μg/ml of pln.247 plasmid. Inset arrow designates region of panel B. B: 400x magnification of region designated
in panel A between existing maxilla (bottom) and new osteoid with marrow space and partially integrated TCP. A line of demarcation can be
discerned between the labels Osteoid and Maxilla. C: 6 wk healing; Left - B-247 treatment of TCP loaded and lyophilized with 50 μg/ml rhBMP-2
plus 100 μg/ml of pln.247 plasmid. Right - TCP loaded and lyophilized with 50 μg/ml BMP-2. No new bone was generated by the TCP particles
activated with only the low-dose BMP-2 (left). Hashed regions represent the original maxillary ridge. C: 6 wk healing; Left - TCP loaded and
lyophilized with 50 μg/ml rhBMP-2 plus 100 μg/ml of the empty-vector plasmid pBI. Right - TCP loaded and lyophilized with 50 μg/ml BMP-2.
Area encircled represents new bone (blue) generated by the bioactivated TCP particles. Bar = 0.5 mm. Pairs of images for B and C are from same
animal. Bar = 0.5 mm.








Figure 10 Masson’s Trichrome stain, 12 wk healing. A: Left - TCP loaded and lyophilized with 50 μg/ml BMP-2. Right - B-247 treatment of
TCP loaded and lyophilized with 50 μg/ml rhBMP-2 plus 100 μg/ml of pln.247 plasmid. Inset arrow designates region of panel B. B: 400x
magnification of region designated in panel A between crest of ridge (towards left) and marrow space. Arrows designate remnant TCP particles
which remain partially integrated with new bone (blue) after 12 weeks. C: Left - TCP loaded and lyophilized with 50 μg/ml BMP-2. Right - B-247
treatment of TCP loaded and lyophilized with 50 μg/ml rhBMP-2 plus 100 μg/ml of pln.247 plasmid. Pairs of images are from the same animal.
Bar = 0.5 mm.
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http://www.biomedcentral.com/1472-6750/12/60wound as neither the core nor the associated GAGs can
be distinguished from those of native perlecan D1 or
other native GAGs with existing tools. These data, there-
fore, have only indirectly implicated the in vivo role of
the recombinant HS or CS in BMP-2 dose-enhancement.
While the GAG characteristics of the rhPln.D1 used
here were shown to be similar whether expressed from
HEK 293 cells or HUVEC [25], the type and character of
GAG can probably be influenced by the cell type and the
environment in which it is expressed [40], although this
has not been systematically described in a recombinant
system yet. Nonetheless, an analysis of the structure/
function relationship, both in vitro and in vivo, is import-
ant to pursue.The B-247 bioactivated TCP appeared to stimulate
intramembranous bone formation that was juxta-
proximal to the particles, (see [41]), and new bone that
was contiguous with the maxilla. There was no evidence
of ectopic bone in this model; the B-247 particles were
associated with the development of mature woven bone
on top of, and integrated with, the maxillary bone. How-
ever, not all B-247 particles were associated with new
bone development; in almost every case the most periph-
eral particles surrounding the developing new bone
remained unassociated with new bone formation. This
observation might be partly attributable to a natural
physiological limitation to volume-increase of the maxil-
lary ridge and a physiologically excessive volume of
Figure 11 Masson’s Trichrome stain. A: 6 wk healing. Left - B-247
treatment of TCP loaded and lyophilized with 50 μg/ml rhBMP-2
plus 100 μg/ml of pln.247 plasmid. Right: InFuse™. B: 12 wk healing.
Left - InFuse™; Right - B-247 treatment of TCP loaded and lyophilized
with 50 μg/ml rhBMP-2 plus 100 μg/ml of pln.247 plasmid. Pairs of
images are from same animal.
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http://www.biomedcentral.com/1472-6750/12/60particles administered throughout the trials. Alterna-
tively, the process of de novo bone formation around the
particles is expansive resulting in less particle density














































Figure 12 Histomorphometric summary of conditons that
included a BMP-2 dose of 50 μg per ml TCP volume (n = 25).
Measured was % increase in maxillary ridge height (y-axis) relative
to the conditions where BMP-2 was combined with either
empty-vector plasmid, no plasmid, or the pln.247 plasmid.unincorporated particles peripherally. It is likely that a
combination of these two phenomena resulted in a
border of some unincorporated particles. The relative
proportion of unincorporated particles was ultimately a
function of the osteogenic capacity of the treatment con-
dition – non-osteogenic TCP conditions resulted in up to
100% unincorporation of particles into new bone, while
the most osteogenic conditions resulted in the majority
of particles being incorporated into new bone. Limitation
of new bone to regions of bioactivated TCP deposition
might also be interpreted as a function of the highly
retentive nature of the particles for the biologics, in part.
The pln.247 plasmid delivered alone on the tricalcium
phosphate particles was not osteogenic. Further, neither
non-demineralized human allograft nor very low doses
of rhBMP-2 on the tricalcium phosphate particles
(<30 μg/ml) were osteogenic with or without the pln.247
plasmid (data not shown). It was apparent, therefore, that
the pln.247 plasmid was not osteogenic when delivered
alone, though not surprising since osteogenesis directly
attributable to augmenting only HS/CS proteoglycan
levels has never been reported.
The model using retired breeders is not common and
was chosen with reason. Declining stem cell populations
and decreased healing potential in these older animals
would theoretically limit the rate and extent of bone
regeneration as compared to what could be expected in
young mammals. Given that these data have direct bear-
ing on repair or augmentation of the jaw, and the major-
ity of those needing oral or periodontal reconstruction
are not young, the use of older animals was deliberate so
as to challenge the technology as it may eventually be
challenged in the clinic.
A body of evidence exists in the literature demonstrat-
ing a role for HSPGs, and perlecan in particular, in cell
adhesion, cell proliferation, cell differentiation, and cell
migration, all of which are crucial to osteoinduction and
wound repair. As cited herein, CSPGs can also have a
similar role. Despite this existing evidence for HSPGs
and CSPGs as potentially valuable adjuncts for a variety
of tissue engineering and wound-healing strategies that
are mediated through growth factor activities, no HS or
CS augmented therapies yet exist.
By therapeutically delivering the cDNA encoding the
proteoglycan core sequence, this technology may over-
come complications in HSPG or CSPG manufacturing
with pharmaceutical consistency. The technology allows
site-specificity and tissue specificity of the post-
translational HS or CS GAG modifications that would
be difficult to predict and provide pharmaceutically. The
FDA has designated the B-247 TCP particles as a com-
bination product, under the regulation of CBER, which
is a first for bone graft devices, as all others are currently
regulated as devices in CDRH.
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A recombinant perlecan domain 1 expressed by the
pln.247 plasmid bound rhBMP-2 tightly and enhanced
BMP-2 activity significantly in vitro. The pln.247 plas-
mid more than quadrupled (4–9 fold) the dose-
effectiveness of BMP-2 osteogenic activity for in vivo de
novo bone generation, and the B-247 formula of TCP,
BMP-2, and pln.247 plasmid was greatly superior in effi-
cacy to TCP and other bone graft products. The B-247
provided more than 5 times as much maxillary ridge
augmentation than InFuse™ using 1/30th of the BMP-2
dose, and the B-247 formula generated new bone with
4 fold greater density than new bone generated by
InFuse™. The B-247 formula generated minimal inflam-
mation and did not cause osteonecrosis in the first
3 weeks post-implant as did InFuse™. The B-247 formula
only generated new bone that was contiguous with the
existing bone and only where the implant material was
placed. It remains to be seen whether HS/CS proteogly-
can technology for BMP-2 activation will be effective in
higher mammals and further research is warranted.
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